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Abstract The incidence of esophageal squamous cell
carcinoma (ESCC) is very high in northeastern Iran. Pre-
viously, we reported a strong familial component of ESCC
among Turkmens, who constitute approximately one-half
of the population of this region. We hypothesized that the
genes which cause Fanconi anemia might be candidate
genes for ESCC. We sequenced the entire coding regions
of 12 Fanconi anemia genes in the germline DNA of 190
Turkmen cases of ESCC. We identified three heterozygous
insertion/deletion mutations: one in FANCD2 (p.Val1233-
del), one in FANCE (p.Val311SerfsX2), and one in FANCL
(p.Thr367AsnfsX13). All three patients had a strong family
history of ESCC. In addition, four patients (out of 746
tested) were homozygous for the FANCA p.Ser858Arg
mutation, compared to none of 1,373 matched controls
(OR = 16.7, 95% CI = 6.2–44.2, P = 0.01). The
p. Lys3326X mutation in BRCA2 (also known as Fanconi
anemia gene FANCD1) was present in 27 of 746 ESCC
cases and in 16 of 1,373 controls (OR = 3.38, 95%
CI = 1.97–6.91, P = 0.0002). In summary, both hetero-
zygous and homozygous mutations in several Fanconi
anemia-predisposing genes are associated with an
increased risk of ESCC in Iran.
Introduction
Esophageal cancer is the eighth most common cancer in the
world and is a significant global health problem (Parkin et al.
2005). The 5-year survival rate for patients with esophageal
cancer is 10–16% (Parkin et al. 2005). A region in north-
eastern Iran at the Caspian Sea littoral has a very high
incidence of esophageal cancer (Saidi et al. 2000; Semnani
et al. 2006), most of which are squamous cell carcinomas.
Previously, we reported a strong familial component of
esophageal squamous cell carcinoma (ESCC) among
Turkmen (Akbari et al. 2006). Turkmens constitute one-half
of the population in this region. The lifetime risk of cancer
was 14% for all individuals in the population and was 34%
for those with a first-degree relative with esophageal cancer
(HR = 2.3, 95% CI = 1.7–3.1, P = 3 9 10-8).
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Fanconi anemia is an autosomal recessive (and in some
cases X-linked) genetic disorder which is characterized by
congenital abnormalities, bone marrow failure, cancer
susceptibility, and cellular hypersensitivity to DNA cross-
linking agents (Joenje and Patel 2001). Squamous cell
carcinomas of the head and neck (HNSCC) and esophagus
are among the most common solid tumors seen in Fanconi
anemia patients (Alter 2003). In cohorts of Fanconi anemia
patients in the USA (Rosenberg et al. 2003) and in
Germany (Rosenberg et al. 2008), the observed:expected
incidence ratios for ESCC were 2,000 and 6,000,
respectively.
Previously, we scanned the coding regions of the
BRCA2 gene (a member of the Fanconi anemia gene
pathway) in the germline DNA of 197 Turkmens with
ESCC (Akbari et al. 2008). We found that the p. Lys3326X
nonsense BRCA2 mutation was more frequent in ESCC
patients than in controls (OR = 6.0, 95% CI = 1.3–28,
P = 0.01) (Akbari et al. 2008). BRCA2 was originally
described as a breast cancer susceptibility gene (Wooster
et al. 1995), but BRCA2 germline mutations have also been
shown to increase the risk of ovarian (Narod 2002),
prostate (Simard et al. 2003), and pancreatic cancers
(Lowenfels and Maisonneuve 2005). BRCA2 is a DNA
repair gene which is involved in homologous recombina-
tion DNA repair (Pellegrini et al. 2002). Polymorphic
micro-satellite markers in the vicinity of BRCA2 show a
high frequency of loss of heterozygosity in ESCCs (Li
et al. 2001). BRCA2 (FANCD1) is actually a member of a
group of at least 13 different proteins which constitute the
Fanconi anemia pathway (Taniguchi and D’Andrea 2006;
Reid et al. 2007; Howlett et al. 2002). Eight of these
proteins (FANCA, B, C, E, F, G, L, and M) form a nuclear
complex, known as the Fanconi anemia core complex,
which is required for monoubiquitination of the FANCI
and FANCD2 complex in response to DNA damage
(Smogorzewska et al. 2007). The other three proteins
[FANCD1 (BRCA2), FANCJ (BRIP1), and FANCN
(PALB2)] are downstream to the FANCI–FANCD2 com-
plex and are involved in DNA repair, through homologous
recombination (Taniguchi and D’Andrea 2006; Reid et al.
2007).
The association of the BRCA2 p. Lys3326X mutation
with the risk of ESCC suggested to us that other genes in
the Fanconi anemia pathway might also be involved in the
high incidence rate of ESCC in northeastern Iran. We
screened the coding exons of 12 Fanconi anemia genes in
the germline DNA of 190 Turkmen ESCC patients. The
identified variants were then studied in 91 additional cases
and in 811 controls, all Turkmen. The variants which
showed an association with the ESCC risk in Turkmen
cases and controls were investigated further in non-Turk-
men cases and controls.
Materials and methods
Study subjects
This report is based on one of several studies on gastric and
esophageal cancers (Islami et al. 2004; Pourshams et al.
2010; Sadjadi et al. 2003) which is underway in Gonbad,
the second largest city of Golestan province, in northeast-
ern Iran and in Ardabil, the largest city in Ardabil province
in northwestern Iran. Turkmens constitute half of the
population in Golestan province, and Persians, Turks,
Sistanies, Balouches, and Kurds constitute the other half
(referred to here as non-Turkmens). Almost all the inhabi-
tants of Ardabil province are Turks. Cases and controls
were collected between August 1, 2001 and May 15, 2008.
The diagnosis of ESCC was confirmed for all cases by
upper gastrointestinal endoscopy and by pathologic eva-
luation of tumor biopsies. The study protocol was approved
by the ethics committees of the Digestive Disease Research
Center (DDRC) of the Tehran University of Medical
Sciences.
First, we sequenced Fanconi anemia genes in 190
Turkmen ESCC patients. Then the potentially deleterious
mutations of Fanconi anemia genes identified in these
patients were genotyped in 91 more Turkmen ESCC
patients and 811 Turkmen healthy controls. We did not
sequence the Fanconi anemia genes in controls. In order to
show that the ESCC-associated variants are not limited to
Turkmen population, variants which showed significant
different frequencies among Turkmen cases and controls
were further studied in 465 and 562 non-Turkmen ESCC
patients and healthy controls, respectively.
Cases
A total of 746 cases were enrolled in this study. There were
281 Turkmen and 220 non-Turkmen ESCC cases from
Gonbad city. Non-Turkmen cases included Persians
(n = 114), Turks (n = 59), Sistanies (n = 28), Balouches
(n = 9), and Kurds (n = 10). In addition, we enrolled 245
Turkish cases from Ardabil, a city in northwestern Iran with
intermediate rates of ESCC (Sadjadi et al. 2003). Ethnicity
was defined as Turkmen, Turk, Persian, Sistani, Balouch, or
Kurd if all four grandparents were from the same ethnic
group for whom the pedigree data were available, otherwise
based on individual’s self-report. The mean age at diagnosis
was 63.6 years (range 25–89 years); 380 cases (50.9%)
were males. Epidemiologic data included smoking status,
use of opium and alcohol, and a family history of cancer.
The cases sequenced for Fanconi anemia genes consisted of
the first 190 Turkmens who were available for testing. The
remaining 91 Turkmen patients were genotyped for
the potentially deleterious variants which were identified in
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the first 190 patients. The 465 non-Turkmen ESCC patients
were genotyped only for those variants which showed
association with ESCC in Turkmens.
Controls
A total of 1,373 controls were recruited to the study: 244
were Turks from Ardabil city, 811 were Turkmen from
Gonbad city, and 318 were non-Turkmen from Gonbad city
[Persians (n = 133), Turks (n = 78), Sistanies (n = 79),
Balouches (n = 19), and Kurds (n = 9)]. 898 controls were
patients referred to local hospitals for a reason other than
cancer, and 475 controls were healthy individuals enrolled
from the Golestan cohort study (Pourshams et al. 2010).
Controls had no personal history of cancer. The mean age for
controls was 55.2 years (range 24–90 years); 700 (51.0%)
were males. The 811 Turkmen controls were genotyped for
potentially deleterious mutations identified from direct
sequencing of Turkmen cases. The remaining 562 controls
were all non-Turkmens, who were tested only for ESCC-
associated variants in Turkmens. Characteristics of the total
of 746 cases and 1,373 controls are presented in Table 1.
Candidate genes sequencing
All Fanconi anemia pathway genes [except BRCA2
(FANCD1) which was studied previously] (Akbari et al.
2008) were selected as candidate genes for sequencing in the
germline DNA (extracted from peripheral blood lympho-
cytes) of the 190 Turkmen ESCC patients. Because of the
large amount of DNA required for this step, the whole-
genome amplified DNA was used for sequencing. REPLI-g
Midi kit (Qiagen, Hilden, Germany) was used for whole-
genome DNA amplification. All identified deleterious
mutations were confirmed by sequencing the original
germline DNA (not whole-genome amplified DNA) sam-
ples. All coding exons of 12 Fanconi anemia genes were
targeted for direct sequencing. These 12 Fanconi anemia
genes contain 36,038 coding base pairs in 239 exons in total
(Supplementary Table 1). All these coding exons except
four exons of FANCD2 gene were amplified in 218 ampli-
cons. We were not able to amplify exons 12, 13, 14, and 20
of FANCD2 gene. This was because of the high homology of
the sequences of these exons and their surrounding intronic
regions with two FANCD2 pseudogenes on both sides of
FANCD2 gene on chromosome 3 (Kalb et al. 2007) that
resulted in unwanted PCR products on amplifying of these
exons in FANCD2. Primers were designed using Primer 3
software (Rozen and Skaletsky 2000) to cover at least 20
base pairs at each 50 and 30 sides of the exons. The amplified
DNA fragments were sequenced by using the BigDye Ter-
minator Cycle Sequencing kit on a ABI 3730xl DNA Ana-
lyzer (Applied Biosystems Co., Foster City, CA, USA).
Candidate variants genotyping
From Fanconi anemia gene variants identified by direct
sequencing of the germline DNA of 190 ESCC patients,
those predicted to be deleterious [12 missense variants
(Table 2), FANCA p.Ser858Arg (Table 3) and 3 insertion/
deletions (Table 4)] were genotyped in 811 Turkmen
controls and 91 more Turkmen cases. Original germline
DNA (not whole-genome amplified DNA) was used for
genotyping. In order to validate our preliminary report on
BRCA2 p. Lys3326X variant (Akbari et al. 2008), we
included this variant as well. We used iPLEX chemistry on
a MALDI-TOF MassARRAY system (Sequenom Inc., San
Diego, CA, USA) for genotyping of variants at this step.
The procedures were performed according to the manu-
facturer’s standard protocol. The cases and controls were
distributed evenly in the DNA plates. All 281 and 811
Turkmen cases and controls, including those 190 cases
which were used for sequencing, were genotyped for
potentially deleterious variants. The sequencing samples
were included as quality control group which their geno-
type calls from MassARRAy genotyping were in 100%
concordance with their sequencing results. The average
genotyping call rate was 99% (ranging from 97 to 100%).
Variants that showed association with ESCC in Turk-
mens (BRCA2 p. Lys3326X and FANCA p.Ser858Arg)
Table 1 Subject characteristics of the ESCC cases and controls
Variable Cases Controls P value
Total number (n) 746 1,373 –
Age, mean (range) 63.6 (25–89) 55.2 (24–90) \0.001
Gender, n (%)
Male 380 (50.9) 700 (51.0) 1.0
Female 366 (49.1) 673 (49.0)
Ethnicity, n (%)
Turkmen 281 (37.7) 811 (59.0) \0.001
Turk 304 (40.7) 322 (23.5)
Persian 114 (15.3) 133 (9.7)
Sistani 28 (3.7) 79 (5.8)
Balouch 9 (1.2) 19 (1.4)
Kurd 10 (1.3) 9 (0.6)
Ever smoker, n (%)
Yes 200 (27.9) 339 (25.0) 0.14
No 516 (72.1) 1,018 (75.0)
Ever opium user, n (%)
Yes 158 (29.1) 239 (20.2) \ 0.001
No 382 (70.9) 943 (79.8)
Ever alcohol drinker, n (%)
Yes 37 (5.0) 57 (4.2) 0.22
No 701 (95.0) 1,307 (95.8)
Hum Genet
123
were genotyped in non-Turkmen cases and controls using
TaqMan genotyping assay (FANCA p.Ser858Arg assay
ID: C_2272037_10, BRCA2 p. Lys3326X assay ID:
C_27537307_20) on ABI 7500 fast real-time system
(Applied Biosystems Co., Foster City, CA, USA). 10%
blinded quality control samples were included in each
plate; the mean concordance rates were 100%. The average
genotyping call rate was 99% (ranging from 98 to 100%).
Table 2 Genotyping results of the potentially deleterious variants in 281 Turkmen cases and 811 Turkmen controls
Gene Variant Cases (281) Controls (811)
Heterozygote, n (%) Homozygote, n (%) Heterozygote, n (%) Homozygote, n (%)
FANCA p.1011Arg[Cys 9 (3.2) 0 (0.0) 36 (4.4) 1(0.1)
FANCB p.335Gly[Glu 19 (6.8) 14 (5.0)
(14)a
48 (5.9) 30 (3.7)
(29)a
FANCC p.515Thr[Ser 5 (1.8) 0 (0.0) 16 (2.0) 0 (0.0)
FANCE p.89Arg[Leu 3 (1.1) 0 (0.0) 4 (0.5) 0 (0.0)
FANCI p.55Pro[Leu 28 (10.0) 1 (0.3) 59 (7.3) 6 (0.7)
FANCI p.876Asp[Gly 6 (2.1) 0 (0.0) 9 (1.1) 0 (0.0)
FANCL p.36Phe[Leu 10 (3.6) 0 (0.0) 26 (3.2) 1 (0.1)
FANCL p.208Asp[Asn 5 (1.8) 0 (0.0) 11 (1.4) 0 (0.0)
FANCM p.175Ser[Phe 58 (20.6) 3 (1.1) 155 (19.1) 11 (1.4)
FANCM p.1644Arg[Gln 6 (2.1) 0 (0.0) 13 (1.6) 0 (0.0)
FANCM p.1812Pro[Ala 85 (30.2) 7 (2.5) 265 (32.7) 23 (2.8)
FANCN p.998Gly[Glu 14 (5.0) 1 (0.3) 44 (5.4) 1 (0.1)
a Because the FANCB gene is located at X chromosome, male carriers of the mutated allele represent like homozygotes while they are
hemizygous. Number in the bracket indicates the number of males with the mutated allele
Table 3 Genotyping results of common variants of Fanconi anemia genes showed association with ESCC risk
Gene,
variant
Turkmens, n (%) Non-Turkmens, n (%) Total, n (%)
Cases
(281)
Controls
(811)
ORa P valuea Cases
(465)
Controls
(562)
ORc P valuec Cases
(746)
Controls
(1,373)
ORc P valuec
FANCA, Ser858Arg
Ser/Ser 249 (88.6) 735 (90.6) 1.00 1.00 427 (91.8) 531 (94.5) 1.00 1.00 676 (90.6) 1,266 (92.2) 1.00 1.00
Ser/Arg 30 (10.7) 76 (9.4) 1.24 0.37 36 (7.7) 31 (5.5) 1.63 0.12 66 (8.8) 107 (7.8) 1.33 0.10
Arg/Arg 2 (0.7) 0 (0.0) 14.76 0.06b 2 (0.5) 0 (0.0) 6.21 0.20b 4 (0.6) 0 (0.0) 16.86 0.01b
Recessive 14.53 0.06b 6.03 0.20b 16.65 0.01b
BRCA2, Lys3326X
Lys/Lys 272 (96.8) 805 (99.3) 1.00 1.00 447 (96.1) 552 (98.2) 1.00 1.00 719 (96.4) 1,357 (98.8) 1.00 1.00
Lys/X 9 (3.2) 6 (0.7) 4.00 0.01 18 (3.9) 10 (1.8) 2.61 0.01 27 (3.6) 16 (1.2) 3.38 0.0002
a P value and odds ratio (OR) were adjusted for age, gender, smoking, and opium use applying multivariate logistic regression analysis
b P value is based on Fisher’s Exact test
c Odds ratio (OR) and P value were adjusted for ethnicity, age, gender, smoking, and opium using multivariate logistic regression analysis
Table 4 Coding singleton insertion/deletions identified in Fanconi anemia genes in germline DNA of 190 Turkmen ESCC patients
Patient Gender Age at
diagnosis
Gene Exon Nucleotide change Protein change Family history of ESCC
(age at diagnosis)
P28266 Male 59 FANCL 14 c.1095_1098dupAATT p. Thr 367AsnfsX13 Brother (55 years), Mother (45 years)
P28569 Male 62 FANCE 4 c.929_930insC p.Val311SerfsX2 Sister (48 years), First Cousin (45 years)
P30843 Female 50 FANCD2 37 c.3697_3699delGTT p.Val1233del Mother (65 years), Uncle (60 years)
Hum Genet
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Copy number analysis
Exon 8 of FANCL gene which contains p.Thr224Ala variant
and exon 27 of FANCA gene which contains p.Ser858Arg
variant were tested for determining copy number using
TaqMan copy number custom design assay on ABI 7500
fast real-time system (Applied Biosystems Co., Foster City,
CA, USA). The primers and probe sequences for exon 8 of
FANCL were F: GTAACATTCAGAAGTAGAGTTTAAT
TAGCT, R: ACTGCATTATTCTGACTTTTTTCTT GTT
CT, P: CAGGAATCGTGGAACAGGTAACT and for exon
27 of FANCA were F: CGGAAGGCCGAGGTCTG, R:
GACAGCCAGCCTGACTCA P: ATGACAGCCAGCCT
GACCCAG. RNase P gene (Part #: 4403326) was used as a
control gene for this assay. Raw data were analyzed for
copy number using Copy Caller software (Applied Bio-
systems Co., Foster City, CA, USA). Original germline
DNA (not whole-genome amplified DNA) was used for
copy number analysis.
Data analysis
Sequencing chromatograms generated by ABI 3730xl DNA
Analyzer instrument were analyzed for variant detection
using Mutation Surveyor software (SoftGenetics LLC., PA,
USA). All sequences were compared to the related NCBI
(http://www.ncbi.nlm.nih.gov) reference sequences (Sup-
plementary Table 1) for variant detection. The chromato-
grams of all the computationally determined variants were
checked manually for confirming the existence of those
variants. The identified variants were searched in NCBI
dbSNP Build 130 for Human to find their related rs#, and
those were not found there considered as novel variants.
All insertion and deletions in the gene coding region,
nonsense variants, and variants located at the splice site
consensus sequences were considered as potentially dele-
terious. Missense variants first were searched in UniProt
Database (http://www.uniprot.org) for determining their
functional effects. If their functional effect were not
known, bioinformatic tools were utilized to predict their
effect. For predicting the functional effect of the missense
variants, we used PolyPhen (Sunyaev et al. 2001) and SIFT
(Ng and Henikoff 2003) bioinformatic tools. Missense
variants predicted to be deleterious by Polyphen or SIFT
algorithms and had a minimum allele frequency (MAF)
[0.5% were considered as potentially deleterious variants.
The MAF [ 0.5% was used to exclude singleton mutations
(private mutations seen in a single individual) which do not
provide enough power for association analysis. The pre-
dicted potentially deleterious variants were genotyped in
more cases and controls.
The permutation version of the exact test was done to
test for Hardy–Weinberg Equilibrium for the genotyped
variants. All genotype comparisons between cases and
controls were done under additive, dominant, and recessive
models in addition to basic allelic and genotypic compar-
ing. The significance level of a = 0.05 was used for all
comparisons. If a comparison was significant in both
Turkmens and non-Turkmens, then a comparison was done
for Turkmens and non-Turkmens in combination. All case–
control comparisons were adjusted for age and ethnicity,
using multivariate logistic regression. Ethnicity was
defined as Turkmen, Turk, Persian, Sistani, Balouch, or
Kurd. An odds ratio (OR) was generated for each com-
parison. In cases with allele frequency of zero in a group,
0.5 added to the frequencies in both side, and then OR was
calculated (continuity corrected). This is a standard epi-
demiologic approach. All analyses were done by SNP
Variation Suit V.7 (Golden Helix Inc., Bozeman, MT,
USA).
Results
All 12 genes in the Fanconi anemia pathway were
sequenced in their entirety in 190 ESCC patients [BRCA2
was studied previously in the same set of samples (Ak-
bari et al. 2008)]. Of the 190 patients, 110 (58%) were
males. Their mean age at diagnosis was 63.9 (range
30–86). All 190 subjects were Turkmens. The charac-
teristic of all cases and controls were shown in Table 1.
There was no difference between the characteristics of
sequenced and non-sequenced cases. All 239 coding
exons of the 12 Fanconi anemia genes, with the exception
of four exons in FANCD2, were sequenced in 218
amplicons (*36 Kbp in total; Supplementary Table 1). A
total of 2,781 nucleotide changes were identified in the
coding regions of the 12 Fanconi anemia genes in the
190 patients. 1,957 variants were in the heterozygous
state and 824 were homozygous. On average, each patient
had 14.6 nucleotide variants within the coding regions of
the 12 Fanconi anemia genes. Considering the lengths of
the coding exons of the Fanconi anemia genes (*36
Kbp), each patient had one nucleotide change at every
*2.5 Kbp. These 2,781 nucleotide changes were present
at 165 distinct loci. Two were insertions (Table 4), one
was a deletion (Table 4), 115 were missense variants
(Supplementary Tables 3, 4), and 47 were silent variants
(Supplementary Tables 5, 6). We did not detect any
nonsense or splicing variant. Of the 165 detected variants,
102 were novel variants which were not reported in
NCBI dbSNP build 130. Details on the number of vari-
ants identified in each gene were shown in Supplemen-
tary Table 2.
Three heterozygous insertion/deletion mutations (Table 4)
were identified, once each in FANCD2 (p.Val1233del),
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FANCE (p.Val311SerfsX2), and FANCL (p.Thr367As-
nfsX13). None of these was found in 811 Turkmen controls.
However, comparisons of the allele frequencies for each
insertion/deletion separately were not significant. All three
patients with an insertion/deletion have at least one affected
first-degree relative with ESCC, compared to 22% (41/190) of
all sequenced samples (OR = 23.1, 95% CI = 7.0–75.9,
P = 0.01). Their mean age at diagnosis was less than that of
the other 187 ESCC patients (57 vs. 64 years) sequenced for
FA genes (Table 4), but the difference was not significant.
A total of 115 missense variants were identified in the
Fanconi anemia genes: 73 were novel mutations (Supple-
mentary Table 3) and 42 were previously reported mis-
sense variants (Supplementary Table 4). Of the 115
missense variants, 62 were singletons, of which 50 were
novels. All singleton missense variants were in the het-
erozygous state, except for p.224Thr[Ala in exon 8 of
FANCL, which was in the homozygous state. The TaqMan
copy number assay confirmed the existence of two copies
of exon 8 and ruled out hemizygosity for this variant.
Although 27 of 62 singleton variants were predicted to be
deleterious by either the Polyphen (Sunyaev et al. 2001) or
SIFT (Ng and Henikoff 2003) algorithms, we did not study
these in controls because of their low frequencies.
Of the 53 missense variants with a minor allele fre-
quency of 0.5% or greater (i.e. at least two carriers were
identified), 12 variants were predicted to be deleterious
using in silico function prediction algorithms. The FANCA
p.Ser858Arg variant is a known cause of Fanconi anemia
(Tamary et al. 2000). The 12 potentially deleterious mis-
sense variants (Table 2) and FANCA p.Ser858Arg variant
as well as the BRCA2 p. Lys3326X identified in our pre-
vious study (Akbari et al. 2008) were genotyped in 91
additional Turkmen cases and in 811 Turkmen controls
(Tables 2, 3). The frequency of the all 12 potentially
deleterious missense variants was the similar in cases and
controls (Table 2). The frequency of the heterozygous
carriers of FANCA p.Ser858Arg was similar in cases and
controls (Table 3). However, we identified two homozy-
gous patients in 281 Turkmen cases while there was no
homozygous patient among 811 Turkmen controls (P =
0.06). The FANCA p.Ser858Arg was then genotyped in 465
additional cases and 562 controls, all non-Turkmens. Two
more homozygotes were detected among non-Turkmen
cases and none among controls. In total, four homozygous
patients for FANCA p.Ser858Arg were identified among
746 ESCC patients (281 Turkmens and 465 non-Turk-
mens), whereas none of 1,373 controls was a homozygote
(OR = 16.7, 95% CI = 6.2–44.2, P = 0.01) (Table 3).
Only one of the four homozygous patients for FANCA
p.Ser858Arg had a family history of ESCC (Table 5). The
TaqMan copy number assay confirmed the existence of two
copies of exon 27 of FANCA gene containing p.Ser858Arg
in all four ESCC patients that ruled out hemizygosity for
this variant in these four samples.
We have previously shown (Akbari et al. 2008) that the
BRCA2 p. Lys3326X truncating variant is associated with
an increased risk of ESCC in 197 cases and 254 controls
(OR = 6.0, 95% CI = 1.3–28, P = 0.01). In total, we
genotyped this variant in 746 cases and 1,371 controls
(including the original samples) (Table 3). The frequency
of BRCA2 p. Lys3326X was 3.6% (27/746) among
ESCC cases and was 1.2% (16/1,373) among controls
(OR = 3.18, 95% CI = 1.70–5.95, P = 0.0002). After
adjusting for ethnicity, age, gender, smoking, and opium
use, carriers of the BRCA2 p. Lys3326X variant have
3.38-fold increased risk of developing ESCC in compar-
ison to non-carriers (95% CI = 1.97–6.91, P = 0.0002)
(Table 3).
Risk factors for ESCC in this region include smoking
and opium use (Nasrollahzadeh et al. 2008). In the subset
of cases and controls with one or more of these risk factors,
the odds ratio associated with the BRCA2 p. Lys3326X
variant was 6.06 (95% CI = 1.68–21.92, P = 0.003).
Among individuals with neither risk factor, the odds ratio
was 2.5 (95% CI = 1.19–5.25, P = 0.01). Although the
interaction was not statistically significant, this suggests
that a gene/environment interaction might be present.
Discussion
Genes in the Fanconi anemia pathway are involved in the
repair of DNA interstrand cross-links (ICLs) (Mirchandani
and D’Andrea 2006). Pathogenic mutations in these genes
are deleterious for both cellular replication and transcrip-
tion processes. The Fanconi anemia core-complex consists
of eight Fanconi anemia proteins (A, B, C, E, F, G, L,
and M) that bind to FANCD2 through its FANCE subunit
(Gordon et al. 2005). After binding of the core-complex to
the FANCD2 protein, the RING-finger-containing FANCL
subunit, which has E3 ligase activity, transfers ubiquitin
from Ube2t to FANCD2 (Alpi et al. 2008). Monoubiqui-
tinated FANCD2 in coordination with RAD51 and other
Fanconi anemia proteins, including BRCA2 (FANCD1),
Table 5 Characteristic of ESCC patients who were homozygous for
FANCA p.858Ser[Arg
Patient Gender Age at
diagnosis
Ethnicity Family history
of ESCC
(age at diagnosis)
P30815 Male 51 Turkmen No
P34433 Female 83 Turkmen No
P35113 Male 61 Turk Brother (58 years)
P35121 Female 42 Turk No
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PALB2 (FANCN), and BRIP1 (FANCJ), promotes error-
free homologous recombination repair (Taniguchi and
D’Andrea 2006).
Bi-allelic inactivation of Fanconi anemia genes in
individuals with the Fanconi anemia syndrome results in
chromosomal instability, hypersensitivity to cross-linking
agents (Joenje and Patel 2001), and an increased risk of
cancers, such as acute myeloid leukemia (AML) and
HNSCC (Alter 2003). There is some evidence that mono-
allelic inactivation of a Fanconi anemia gene also increases
chromosome breakage rates in response to cross-linking
agents (Pearson et al. 2001) and increases the release of
fragmented DNA after exposure to X-radiation (Djuzenova
et al. 2001). Mono-allelic inactivation of Fanconi anemia
genes (i.e. heterozygous parents of Fanconi anemia cases)
is also reported to be associated with an increased risk of
different cancers, including early-onset pancreatic cancer
(Couch et al. 2005). Relatives of Fanconi anemia patients
in complementation group C who were heterozygous
FANCC mutation carriers showed an increased risk of
breast cancer (Tischkowitz et al. 2008). Heterozygous
FANCA deletions were detected in adult AML cells 35-fold
more frequently than expected (Tischkowitz et al. 2004).
Here, we also identified germline mono-allelic mutation of
FANCD2, FANCE, FANCL, and BRCA2 (FANCD1) and
bi-allelic mutation of FANCA to be associated with of
increased risk of ESCC.
The frequency of heterozygous carriers of FANCA
p.Ser858Arg was similar among ESCC cases (8.8%) and
controls (7.8%); however, we found four homozygous
patients in 746 ESCC patients and no homozygote among
1,373 controls (OR = 16.7, 95% CI = 6.2–44.2, P = 0.01).
The FANCA protein interacts directly with the FANCB,
FANCG, and FANCL proteins of the core-complex (Med-
hurst et al. 2006). Bi-allelic mutations of FANCA gene are
responsible for *60% of cases of Fanconi anemia (Levitus
et al. 2006). The p.Ser858Arg mutation was first identified in
a German Fanconi anemia patient for whom the other
mutated allele was not identified (Wijker et al. 1999) and,
recently, was also found in an Italian Fanconi anemia type A
patient who carried the 3762-3763insG as the other FANCA
allele (Savino et al. 2003). The cell line of the Italian patient
showed a decreased (but detectable) amount of FANCA
protein; however, FANCD2 protein was present only in its
non-ubiquitinated form (Savino et al. 2003). This suggests a
deleterious effect of p.Ser858Arg on FANCA protein func-
tion although the evidences are not conclusive to confirm
this. In spite of suggestive deleterious effect of this mutation
and possibility of existing mild FA symptoms in four patients
who were homozygous for this variant in our study, because a
chromosome breakage test has not been performed, we
cannot confirm whether these patients were affected with
FA. ESCC is one of the most common solid tumors seen in
Fanconi anemia patients (Alter 2003; Rosenberg et al. 2003,
2008). This observation that the four possibly Fanconi ane-
mia patients presented with ESCC late in life (Table 5) is
consistent with the fact that all previously reported Fanconi
anemia patients diagnosed in their 50s and higher were from
complementation group A (Neveling et al. 2009). However,
the observation is inconsistent with the report of Jewish
Fanconi anemia patients who were also homozygous for the
p.Ser858Arg mutation and who presented with severe dis-
ease in childhood (Tamary et al. 2000). A possible expla-
nation for this discrepancy is that Jewish patients might not
have been true homozygous, but were hemizygous with a
large deletion of the other allele, which was missed by
sequencing. FANCA is rich for Alu sequences, an intragenic
large deletions resulting from HRR are common in FANCA
genes (Yagasaki et al. 2004). In fact, the intragenic large
deletions constitute up to one-thirds of FANCA mutations in
FA patients (Calle´n et al. 2004). Fanconi anemia patients
with FANCA null alleles are diagnosed earlier in life with
more severe symptoms, in comparison to Fanconi anemia
patients with dysfunctional FANCA missense mutations
(Adachi et al. 2002). We confirmed the homozygous status of
p.Ser858Arg mutation in all four ESCC patients by deter-
mining the copy number of exon 27 of FANCA. Another
possible explanation could be that this mutation has different
phenotypic presentation among different populations. For
example, the FANCC IVS4 ? 4 A[T mutation showed a
severe phenotype in the Ashkenazi Jewish population and
a mild phenotype among Japanese patients (Futaki et al.
2000).
We identified three singleton heterozygous insertion/
deletions in FANCD2 (p.Val1233del), FANCE (p.Val311
SerfsX2), and FANCL (p.Thr367AsnfsX13). The FANCL
p.Thr367AsnfsX13 results from the duplication of four
nucleotides at exon 14 just after RING-finger domain. This
duplication results in a protein with nine changed residues
at its C-terminal and three residues longer than the wild-
type FANCL protein. The FANCL p.Thr367AsnfsX13 was
reported in a Fanconi anemia patient in a compound het-
erozygous state with a deletion of the other allele (Ali et al.
2009). The FANCE p.Val311SerfsX2 results in truncation
of 224 residues at the C-terminus of the protein. This
truncated protein lacks the helical structures required for
binding FANCD2 (Nookala et al. 2007). The FANCD2
p.Val1233del is an in-frame deletion of valine at exon 37.
A deletion of eight residues at codon 1228–1235 resulted in
an aberrant splicing was reported in a Fanconi anemia
patient (Kalb et al. 2007). This suggests that valine at
codon position 1233 is located in an important functional
region of FANCD2, and its deletion could be deleterious
for the protein function. None of these three insertion/
deletions was found in 811 Turkmen controls. Although the
allele frequency differences were not significant for each
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insertion/deletion, this could be genetically meaningful,
and these mutations have an effect on predisposing the
patients to ESCC. Showing a loss of heterozygosity for
these alleles in the tumor tissue samples of the patients
could confirm the causal effect of these insertion/deletions
for ESCC; however, we did not have access to the tumor
samples. Each of the three ESCC patients with these
mutations had a strong family history of ESCC in com-
parison to the rest of the sequenced samples (P = 0.01). It
would have been helpful to show the co-segregation of
these insertion/deletions in other affected family members.
Unfortunately, all the affected family members had died.
The FANCD2, FANCE, and FANCL proteins are criti-
cal components of the Fanconi anemia pathway. FANCD2
is the key protein of the Fanconi anemia pathway that its
monoubiquitination initiates downstream DNA repair, and
FANCE and FANCL are core-complex subunits which
bind to FANCD2 (Gordon et al. 2005) and transfer an
ubiquitin molecule from Ube2t to FANCD2 (Alpi et al.
2008). FANCD2 and FANCL are the most conserved
Fanconi anemia genes between human and zebrafish and
are the only Fanconi anemia genes which their homologs
identified in urochordate C. Intestinalis (Titus et al. 2006).
We confirmed our previous finding of an association of
BRCA2 p. Lys3326X with ESCC (Akbari et al. 2008) in a
much larger sample size, and we validated its association
among non-Turkmens as well. The BRCA2 p. Lys3326X
nonsense mutation increased the risk of ESCC by threefold
(OR = 3.15, 95% CI = 1.97–6.91, P = 0.0002). In the
subset of cases and controls who smoke or use opium, the
odds ratio associated with the BRCA2 p. Lys3326X muta-
tion was increased to 6.1 (95% CI = 1.7–22, P = 0.003).
Although the BRCA2 p. Lys3326X mutation does not
appear to predispose to breast cancer (Mazoyer et al. 1996),
individuals with this specific truncating mutation have been
reported to be at increased risk for familial pancreatic
cancer (OR = 4.8, 95% CI = 1.3–19, P \ 0.01) (Martin
et al. 2005) and for lung cancer (OR = 1.72, 95%
CI = 1.15–2.57, P = 0.007) (Rudd et al. 2006). To our
knowledge, the variant has not been seen elsewhere in
esophageal cancer patients. It is of interest that these three
sites (esophagus, lung, and pancreas) are all associated
with tobacco smoking.
The p. Lys3326X variant results in the truncation of 93
amino acids from the C-terminal of the BRCA2 protein.
Mice with a homozygous deletion of exon 27 were sus-
ceptible to various types of solid tumors, but not mammary
tumors (McAllister et al. 2002). This is consistent with this
observation that the BRCA2 p. Lys3326X mutation pre-
disposes to malignant tumors of the pancreas, lung, and
esophagus, but not to breast cancer in humans. Moreover,
there is an extensive phenotypic overlap between mice
which are homozygous for a truncating mutation at the
C-terminal of Brca2 protein and Fancd2 knockout mice
(McAllister et al. 2002; Houghtaling et al. 2003). These
observations suggest that BRCA2 p. Lys3326X mutation
with a mechanism related to Fanconi anemia pathway
might increase the risk of esophageal cancer.
In summary, we identified five patients with a Fanconi
anemia gene mutation among 190 sequenced ESCC patients
(2.6%, 95% CI = 0.9–6.2). Three patients had heterozygous
insertion/deletion mutations in FANCD2, FANCE, and
FANCL, and two patients were homozygous for FANCA
p.Ser858Arg missense mutation. Four of these patients had
positive family history of ESCC. Considering the total
number of patients (129 out of 190) with family history of
ESCC in their first- or second-degree relatives, Fanconi
anemia gene mutations account for 3.1% (4/129) of the
familial cases in this population. However, if we include the
seven carriers of the BRCA2 p. Lys3326X identified among
familial cases, then mutations of Fanconi anemia pathway
genes would be responsible for 8.5% of the familial cases.
Our findings have potential implication on the treatment
of ESCC patients. ESCC patients with heterozygous
mutations of Fanconi anemia genes might benefit from
treatment with DNA cross-linking chemotherapeutic drugs,
such as cis-platin and mitomycin C, or from a PARP [poly
(ADP-ribose) polymerase] inhibitor (McCabe et al. 2003).
However, these drugs might also cause toxic reactions in
Fanconi anemia patients. Fanconi anemia patients are also
sensitive to ionizing radiation as a result of the induction of
double-strand DNA breaks. A 30-year-old woman with a
carcinoma of the tongue and undiagnosed Fanconi anemia
developed severe mucositis following radiotherapy (Alter
et al. 2005). Presently, chemotherapy and radiotherapy are
the main remedies for treating or down-staging of ESCC
patients before surgery with occasional severe side effects
(Alter et al. 2005; Murphy et al. 2008), and it is important
to evaluate if their similar toxicities are observed in ESCC
patients with variants in the FA genes who are treated with
these agents.
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